Search Results - "Redman, Mary"

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A by Reckamp, Karen L, Redman, Mary W, Dragnev, Konstantin H, Minichiello, Katherine, Villaruz, Liza C, Faller, Bryan, Al Baghdadi, Tareq, Hines, Susan, Everhart, Leah, Highleyman, Louise, Papadimitrakopoulou, Vassiliki, Neal, Joel W, Waqar, Saiama N, Patel, Jyoti D, Gray, Jhanelle E, Gandara, David R, Kelly, Karen, Herbst, Roy S

“…Resistance to immune checkpoint inhibition (ICI) in advanced non-small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular…”
Get full text

The Master Protocol Concept by Redman, Mary W, Allegra, Carmen J

“…During the past decade, biomedical technologies have undergone an explosive evolution—from the publication of the first complete human genome in 2003, after…”
Get full text

Moving Toward Rationale Phase 3 Designs for Advanced NSCLC by Ferreira, Marion, Redman, Mary W, Reckamp, Karen L

Get more information

Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study by Paulson, Kelly G., Lewis, Christopher W., Redman, Mary W., Simonson, William T., Lisberg, Aaron, Ritter, Deborah, Morishima, Chihiro, Hutchinson, Kathleen, Mudgistratova, Lola, Blom, Astrid, Iyer, Jayasri, Moshiri, Ata S., Tarabadkar, Erica S., Carter, Joseph J., Bhatia, Shailender, Kawasumi, Masaoki, Galloway, Denise A., Wener, Mark H., Nghiem, Paul

“…BACKGROUND Merkel cell carcinoma (MCC) is an aggressive skin cancer with a recurrence rate of >40%. Of the 2000 MCC cases per year in the United States, most…”
Get full text

T‐cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death‐ligand 1 expression in patients with soft tissue sarcomas by Pollack, Seth M., He, Qianchuan, Yearley, Jennifer H., Emerson, Ryan, Vignali, Marissa, Zhang, Yuzheng, Redman, Mary W., Baker, Kelsey K., Cooper, Sara, Donahue, Bailey, Loggers, Elizabeth T., Cranmer, Lee D., Spraker, Matthew B., Seo, Y. David, Pillarisetty, Venu G., Ricciotti, Robert W., Hoch, Benjamin L., McClanahan, Terrill K., Murphy, Erin, Blumenschein, Wendy M., Townson, Steven M., Benzeno, Sharon, Riddell, Stanley R., Jones, Robin L.

“…BACKGROUND Patients with metastatic sarcomas have poor outcomes and although the disease may be amenable to immunotherapies, information regarding the…”
Get full text

Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR -Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403 by Goldberg, Sarah B, Redman, Mary W, Lilenbaum, Rogerio, Politi, Katerina, Stinchcombe, Thomas E, Horn, Leora, Chen, Everett H, Mashru, Sandeep H, Gettinger, Scott N, Melnick, Mary Ann, Herbst, Roy S, Baumgart, Megan A, Miao, Jieling, Moon, James, Kelly, Karen, Gandara, David R

“…The irreversible ErbB family tyrosine kinase inhibitor (TKI) afatinib plus the EGFR monoclonal antibody cetuximab was previously shown to overcome resistance…”
Get full text

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 by Herbst, Roy S, Gandara, David R, Hirsch, Fred R, Redman, Mary W, LeBlanc, Michael, Mack, Philip C, Schwartz, Lawrence H, Vokes, Everett, Ramalingam, Suresh S, Bradley, Jeffrey D, Sparks, Dana, Zhou, Yang, Miwa, Crystal, Miller, Vincent A, Yelensky, Roman, Li, Yali, Allen, Jeff D, Sigal, Ellen V, Wholley, David, Sigman, Caroline C, Blumenthal, Gideon M, Malik, Shakun, Kelloff, Gary J, Abrams, Jeffrey S, Blanke, Charles D, Papadimitrakopoulou, Vassiliki A

“…The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous…”
Get full text

Incidence of Suicide in Persons With Cancer by MISONO, Stephanie, WEISS, Noel S, FANN, Jesse R, REDMAN, Mary, YUEH, Bevan

“…The purpose of this study was to characterize suicide rates among patients with cancer in the United States and identify patient and disease characteristics…”
Get full text

Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol by Redman, Mary W, Papadimitrakopoulou, Vassiliki A, Minichiello, Katherine, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Vokes, Everett, Ramalingam, Suresh, Leighl, Natasha, Bradley, Jeff, Miao, Jieling, Moon, James, Highleyman, Louise, Miwa, Crystal, LeBlanc, Michael L, Malik, Shakun, Miller, Vincent A, Sigal, Ellen V, Adam, Stacey, Wholley, David, Sigman, Caroline, Smolich, Beverly, Blanke, Charles D, Kelly, Karen, Gandara, David R, Herbst, Roy S

“…The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for…”
Get full text

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124 by LARA, Primo N, NATALE, Ronald, CHANSKY, Kari, GANDARA, David R, CROWLEY, John, JOSEFLENZ, Heinz, REDMAN, Mary W, CARLETON, Jane E, JETT, James, LANGER, Corey J, KUEBLER, J. Philip, DAKHIL, Shaker R

“…Irinotecan plus cisplatin (IP) improved survival over etoposide plus cisplatin (EP) in Japanese patients with extensive-stage small-cell lung cancer (E-SCLC)…”
Get full text

Racial disparities in the screening mammography continuum within a heterogeneous health care system by Ganguly, Anisha P., Baker, Kelsey K., Redman, Mary W., McClintock, Adelaide H., Yung, Rachel L.

“…Abstract Background Decreased mammography drives breast cancer disparities. Black women have lower rates of mammography completion than White women, and this…”
Get full text

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI-Treated Patients with EGFR-Mutant NSCLC (SWOG S1403) by Mack, Philip C, Miao, Jieling, Redman, Mary W, Moon, James, Goldberg, Sarah B, Herbst, Roy S, Melnick, Mary Ann, Walther, Zenta, Hirsch, Fred R, Politi, Katerina, Kelly, Karen, Gandara, David R

“…Dynamic changes in circulating tumor DNA (ctDNA) are under investigation as an early indicator of treatment outcome. Serial plasma ctDNA (baseline, 8 weeks,…”
Get full text

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy) by Aggarwal, Charu, Redman, Mary W, Lara, Jr, Primo N, Borghaei, Hossein, Hoffman, Philip, Bradley, Jeffrey D, Newman, 3rd, Alfred J, Feldman, Marvin J, Minichiello, Katherine, Miao, Jieling, Mack, Philip C, Papadimitrakopoulou, Vassiliki A, Herbst, Roy S, Kelly, Karen, Gandara, David R

“…S1400D is a biomarker-driven therapeutic substudy of Lung-MAP evaluating the fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with…”
Get more information

Scientific Advances in Lung Cancer 2015 by Tsao, Anne S, Scagliotti, Giorgio V, Bunn, Jr, Paul A, Carbone, David P, Warren, Graham W, Bai, Chunxue, de Koning, Harry J, Yousaf-Khan, A Uraujh, McWilliams, Annette, Tsao, Ming Sound, Adusumilli, Prasad S, Rami-Porta, Ramón, Asamura, Hisao, Van Schil, Paul E, Darling, Gail E, Ramalingam, Suresh S, Gomez, Daniel R, Rosenzweig, Kenneth E, Zimmermann, Stefan, Peters, Solange, Ignatius Ou, Sai-Hong, Reungwetwattana, Thanyanan, Jänne, Pasi A, Mok, Tony S, Wakelee, Heather A, Pirker, Robert, Mazières, Julien, Brahmer, Julie R, Zhou, Yang, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A, Redman, Mary W, Wynes, Murry W, Gandara, David R, Kelly, Ronan J, Hirsch, Fred R, Pass, Harvey I

“…Lung cancer continues to be a major global health problem; the disease is diagnosed in more than 1.6 million new patients each year. However, significant…”
Get more information

Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905) by Tsao, Anne S, Miao, Jieling, Wistuba, Ignacio I, Vogelzang, Nicholas J, Heymach, John V, Fossella, Frank V, Lu, Charles, Velasco, Mario R, Box-Noriega, Brandy, Hueftle, James G, Gadgeel, Shirish, Redman, Mary W, Gandara, David R, Kelly, Karen

“…Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca,…”
Get full text

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study by Herbst, Roy S, Redman, Mary W, Kim, Edward S, Semrad, Thomas J, Bazhenova, Lyudmila, Masters, Gregory, Oettel, Kurt, Guaglianone, Perry, Reynolds, Christopher, Karnad, Anand, Arnold, Susanne M, Varella-Garcia, Marileila, Moon, James, Mack, Philip C, Blanke, Charles D, Hirsch, Fred R, Kelly, Karen, Gandara, David R

“…EGFR antibodies have shown promise in patients with advanced non-small-cell lung cancer (NSCLC), particularly with squamous cell histology. We hypothesised…”
Get full text

Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012 by Pang, Herbert H, Wang, Xiaofei, Stinchcombe, Thomas E, Wong, Melisa L, Cheng, Perry, Ganti, Apar Kishor, Sargent, Daniel J, Zhang, Ying, Hu, Chen, Mandrekar, Sumithra J, Redman, Mary W, Manola, Judith B, Schilsky, Richard L, Cohen, Harvey J, Bradley, Jeffrey D, Adjei, Alex A, Gandara, David, Ramalingam, Suresh S, Vokes, Everett E

“…Purpose Under-representation of elderly, women, and racial/ethnic minority patients with cancer in clinical trials is of national concern. The goal of this…”
Get full text

B7-H3 is widely expressed in soft tissue sarcomas by Lynch, Meghan M, Al-Marayaty, Rusul, Obeidin, Farres, Alexiev, Borislav A, Chen, Eleanor Y, Viveiros, Pedro, Schroeder, Brett A, Hudkins, Kelly, Fan, Timothy M, Redman, Mary W, Baker, Kelsey K, Jour, George, Cranmer, Lee D, Pollack, Seth M

“…Targeted therapy development in soft tissue sarcoma (STS) has been burdened by the heterogeneity of this group of rare tumors. B7 homolog 3 protein (B7-H3) is…”
Get full text

Racial and sex differences in tumor genomics in urothelial carcinoma by Nyame, Yaw A, Baker, Kelsey K, Montgomery, Bruce, Grivas, Petros, Redman, Mary W, Wright, Jonathan L

“…Differences in bladder cancer outcomes have been demonstrated by sex and race/ethnicity, with studies showing a higher burden of adverse outcomes among women…”
Get full text

Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer by Yuan, Zixu, Baker, Kelsey, Redman, Mary W, Wang, Lei, Adams, Scott V, Yu, Ming, Dickinson, Brandon, Makar, Karen, Ulrich, Neli, Böhm, Jürgen, Wurscher, Michelle, Westerhoff, Maria, Medwell, Steve, Moonka, Ravi, Sinanan, Mika, Fichera, Alessandro, Vickers, Kathy, Grady, William M

“…Background: Plasma microRNAs (miRNAs) are promising non-invasive biomarkers for colorectal cancer (CRC) prognosis. However, the published studies to date have…”
Get full text